scPharmaceuticals (SCPH) to Release Quarterly Earnings on Wednesday

scPharmaceuticals (NASDAQ:SCPH) is projected to issue its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

scPharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.04). The firm had revenue of $16.04 million during the quarter, compared to analyst estimates of $15.41 million. scPharmaceuticals had a negative return on equity of 1,647.86% and a negative net margin of 183.55%. On average, analysts expect scPharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

scPharmaceuticals Stock Performance

scPharmaceuticals stock opened at $5.67 on Wednesday. The firm has a market capitalization of $302.20 million, a price-to-earnings ratio of -3.13 and a beta of 0.31. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $6.28. The stock’s fifty day moving average is $5.63 and its two-hundred day moving average is $4.56.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Maxim Group lowered shares of scPharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of scPharmaceuticals in a research note on Wednesday, October 8th. Craig Hallum lowered scPharmaceuticals from a “buy” rating to a “hold” rating and set a $6.00 price target on the stock. in a research note on Monday, August 25th. HC Wainwright cut shares of scPharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $5.35 target price on the stock. in a research report on Friday, August 29th. Finally, Wall Street Zen raised shares of scPharmaceuticals to a “hold” rating in a research report on Saturday, October 11th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, scPharmaceuticals presently has an average rating of “Reduce” and an average price target of $7.78.

Hedge Funds Weigh In On scPharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its holdings in shares of scPharmaceuticals by 5.8% during the 2nd quarter. Rhumbline Advisers now owns 54,500 shares of the company’s stock valued at $208,000 after acquiring an additional 3,001 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of scPharmaceuticals by 9.0% during the second quarter. Captrust Financial Advisors now owns 43,746 shares of the company’s stock worth $167,000 after purchasing an additional 3,621 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of scPharmaceuticals during the second quarter worth about $121,000. Comerica Bank lifted its stake in shares of scPharmaceuticals by 22.1% during the first quarter. Comerica Bank now owns 38,662 shares of the company’s stock worth $102,000 after purchasing an additional 7,000 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of scPharmaceuticals during the first quarter worth about $76,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.